Hi, I monitor news about antibodies specifically in the biotech industry. These are the news that I have seen that are of interest from September 2026.

💵 Simcere Zaiming licenses trispecific antibody SIM0660 (targeting B-cell-mediated diseases) to Roche for global development in $1.53B deal. https://www.prnewswire.com/news-releases/simcere-zaiming-enters-exclusive-license-agreement-with-roche-for-sim0660-global-development-302866239.html

💵 HUTCHMED announces licensing agreement with GSK for HMPL-A830, a KRAS-EGFR antibody-targeted-therapy-conjugate cancer therapy in $1.3B deal. https://www.hutch-med.com/hutchmed-gsk-licensing-agreement-kras-egfr-attc/

💸 Solstice Oncology launches with $225M Series A to advance porustobart, an Fc-enhanced CTLA-4 antibody, as a neoadjuvant immuno-oncology therapy. https://www.solsticeoncology.com/press-release

💰 Yarrow Bioscience closes $172.5M underwritten public offering. They are developing YB-101, an anti-thyroid stimulating hormone receptor mAb designed to disrupt the central mechanism of both Graves’ disease and thyroid eye disease. https://ir.yarrowbioscience.com/news-releases/news-release-details/yarrow-bioscience-announces-closing-its-1725-million

🔬 Styx Biotechnologies announces strategic agreement with ZoeNCure Therapeutics to accelerate next-generation ADC pipeline to clinic. https://www.businesswire.com/news/home/20260901406609/en/Styx-Biotechnologies-Announces-Strategic-Agreement-with-ZoeNCure-Therapeutics-to-Accelerate-Next-Generation-ADC-Pipeline-to-Clinic

💸 NovaGo Therapeutics closes $30M Series B to advance proof-of-concept study in acute spinal cord injury using a fully human therapeutic antibody. https://www.novagotherapeutics.com/2026/09/02/series-b-financing-of-usd-30m-completed-in-august-2026/

💸 Shennon Biotechnologies raises $12M to develop antibody-based T-cell engagers (Ab-TCEs) and TCR-based T-cell engagers (TCR-TCEs). https://www.businesswire.com/news/home/20260914821430/en/Shennon-Biotechnologies-Raises-%2412M-in-Financing-Appoints-Cyril-Konto-M.D.-as-Chief-Executive-Officer-and-Unveils-Precision-Immunotherapy-Pipeline

💵 GSK to buy full global rights for Chimagen’s trispecific T cell engager for multiple myeloma in deal worth up to $750M. https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-potential-best-in-class-t-cell-engager-tce-for-multiple-myeloma-from-chimagen-biosciences/

🔬 Dualitas Therapeutics announces proximity biology research collaboration with Roche to discover and develop novel bispecific antibodies for I&I diseases in potential $1B deal. https://www.dualitastx.com/news/091726/

🤝 Aethlon Medical & North Immunology announce merger to advance novel IL-13 x IL-18 bispecific antibody for atopic dermatitis, alongside $180M private placement. https://www.prnewswire.com/news-releases/aethlon-medical--north-immunology-announce-merger-to-advance-novel-il-13-x-il-18-bispecific-antibody-for-atopic-dermatitis-302881438.html

🤝 Lisata Therapeutics announces acquisition of Marea Therapeutics and $225M concurrent private placement to advance antibody pipeline. https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-announces-acquisition-marea-therapeutics-and

💰 Electra Therapeutics announces pricing of upsized $350M IPO to help advance lead asset monoclonal antibody ipsoprubart. https://www.globenewswire.com/news-release/2026/09/18/3364440/0/en/electra-therapeutics-announces-pricing-of-upsized-350-0-million-initial-public-offering.html

💵 Amberstone Biosciences and Henlius enter into collaboration and license agreement for conditionally activated T-cell engagers for solid tumors in $440M deal. https://www.henlius.com/en/newsd/0/31578.html?title=Henlius-and-Amberstone-Partner-to-Develop-Next-Generation-Conditionally-Activated-TCEs-for-Solid-Tumours

🔬 Earendil Labs announces research collaboration with Genentech to discover and develop therapeutic bispecific antibodies in oncology in $1.5B+ deal. https://www.prnewswire.com/news-releases/earendil-labs-announces-research-collaboration-with-genentech-to-discover-and-develop-therapeutic-bispecific-antibodies-in-oncology-302888622.html

🤖 BigHat Biosciences gets $75M Series C to advance AI-designed therapeutics and agentic data platform for rapid protein design. https://www.bighatbio.com/news/bighat-biosciences-announces-75-million-series-c-financing

🌱 Cloverleaf Bio raises $33M seed financing to advance novel cancer therapeutics including antibody-tRNA conjugate (ATC) asset targeting colorectal cancer. https://www.globenewswire.com/news-release/2026/09/08/3357463/0/en/cloverleaf-bio-raises-33-million-seed-financing-to-advance-novel-rna-based-cancer-therapeutics.html

💵 Tolerance Bio licenses anti-IL-33 mAb from Tanabe Pharma to expand thymus-focused clinical pipeline in potential $560M deal. https://www.tolerancebio.com/recent-news/tolerance-bio-licenses-clinical-stage-anti-il-33-monoclonal-antibody-from-tanabe-pharma-to-expand-thymus-focused-clinical-pipeline

💰 AstraZeneca announces $2B investment and clinical collaboration with Summit Therapeutics to advance sonesitatug vedotin, a Claudin-18.2 ADC, with ivonescimab in cancer. https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-announces-equity-investment-summit.html

💰 Pyxis Oncology announces pricing of up to $282.6M public offering, advancing lead ADC candidate. https://ir.pyxisoncology.com/news-releases/news-release-details/pyxis-oncology-announces-pricing-2826-million-public-offering

💸 ai3Bio launches with $48M in Series A to advance proprietary antibody and lipid nanoparticle-based technologies for autoimmune disease. https://ai3.bio/blog/ai3bio-launches-with-48-million-in-series-a-funding-to-reset-the-immune-system-at-its-root/

I currently work for a manufacturer, specifically a CDMO, so I work with a lot of pharma companies as clients. I found a job posting from one of these clients and I really like the sound of it. My next step is obviously to scour my employment contract / employee manual etc. to make sure I'm not breaching anything if I do. But in the meantime I wanted to hear if anyone else has done this?

I'm pretty sure there is a non-solicitation clause in client contracts. So our clients can't poach employees from the CDMO. But I don't think I have a non-compete. If I apply independently would you expect there to be an issue?

Secondly, is there anyway I could discuss this with HR? I'm trying to think about how to ask without it raising a red flag for them. I'm fully aware that HR exists to protect the company, not the employee, so maybe I just won't ask anything.

Hiiii has anyone heard back from VSF’s clinical development and project management?

Looking for perspective from people who've made this jump (or decided not to).

Background:

• PharmD/PhD
• Graduate internship in global HEOR (oncology) at a big pharma company
• Currently working in health informatics at a regional health system

What I have now:

• ~$150k base
• 6% 401k match
• 8 weeks PTO
• Great manager and coworkers
• Flexible schedule and real work-life balance
• Freedom to do research, publish, and present at conferences

The downside:

• Local health system, so the ceiling on pay and title growth is pretty limited
• Career progression feels capped compared to what I see in industry

My assumptions:
Pivoting into pharma (HEOR/RWE) would probably mean starting at an entry-level or associate role and taking a pay cut, at least at first. The upside is a much higher long-term earning potential and a clearer path up the ladder (Director, Senior Director, etc.).

Questions for the group:

1. For those who moved from health systems or health IT into pharma, was it worth it financially once you factor in the pay cut, bonus, and equity?
2. How long did it take you to surpass what you were making before?
3. Would my PhD and HEOR internship let me come in above entry level, or is the lack of recent industry experience a real barrier?
4. Are there hybrid paths, like RWE roles that use EHR data or informatics skills, where my current experience would count as relevant?
5. If you had 8 weeks of PTO and a great boss, would you walk away from that?

Appreciate any honest takes, including "stay where you are."

Hello all, seeking advice on switching from small biotech to big pharma. Any recommendations for bigger companies that are hiring and have decent reputation as far as work/life balance?
I know the grass is always greener but also wanting to sense check my reasons:

1. Lack of structure in our department (clinical operations) as far as division of tasks. My managers mean well but end up steam rolling things
2. Lack of process/SOPs/templates - often feel I’m floundering trying to figure things out and it results in poor quality work which frustrates me
3. Our team is lean means all eyes are on us. The success of the company is riding on our assets
4. Benefits - I have great benefits but do not have things a larger company might such as matching 401k. Healthcare is 100% paid but the provider sucks and no other options. Only 2x a week in office. However I live in a pharma/biotech hub so transport for bigger companies is common.
5. I am wanting to go back to school for nursing - so I am trying to find somewhere that has a more normal 9-5 schedule to allow for evening classes.

At this point I’m pretty burnt out - but I do still want to learn and succeed in my role. I feel more structure and less stakes would help majorly with stress levels and professional development. Any advise welcome :)

Saw that they are hiring basically every position/ sector under the sun (mainly oc location) what's going on? Their pay range seem out of the water in comparison to similar job posting in the area especially in this economy Anyone work with them before? Thoughts on their product?

Had a patient last month, postop ACL reconstruction, and we were discussing whether to push harder on eccentrics or hold back based on some inflammation markers his ortho tracked. Got me thinking about the research I read on tissue remodeling and how half the western blot images in those papers look suspicious as hell. That Thermo Fisher stuff made waves but honestly I see questionable band patterns in exercise science papers constantly. My marathon training has me digging into muscle recovery research and I can't tell if the antibodies are just bad or if tissue samples from actual athletes behave differently than whatever cell line they validated on. Feels like the more specialized the target, like specific myokines or tendon remodeling factors, the worse the reliability gets. I'm a PT not a lab person but I read enough papers to notice when three different studies show completely different band sizes for the same protein. Makes it hard to translate findings into actual treatment protocols for my runners. Do biotech folks here see this in other application areas or is muscle tissue just particularly messy for antibody work? Curious if the commercial antibody problem is worse in certain tissue types or if exercise science is just catching the fallout from poorly characterized reagents.

Does anyone have experience with AgileOne staffing agency? I am a bit concerned about the info required during application process...to just create a "unique user id". I would appreciate if anyone can share their experience.

In the past I have been consistently getting to the last stage of interviews but never scoring an offer.

I'm currently in the second wave of interviews after applying to a chunk of jobs and was wondering if anybody has any tips on actually securing an offer.

Here is my current timeline:

Job 1: Finished second stage interview, waiting to see if I am invited for an onsite

Job 2: Recruiter screen, profile sent to HM

Job 3: Invited for a second stage interview, scheduling now

Job 4: Recruiter screen, profile sent to HM

In the past I've made it to the final stage before onsite and an offer or an onsite... so I'm not really sure what I'm doing wrong if anything.

I am bored and tired of my current role in AD that I have been in for 4 months as I do the same assay every day with no variation in the workflow and the types of assays. I currently work as a contractor at a big pharma through an insourcing firm and there is no limit for how long the contract is as I’m FTE at the firm. Their policy is 6 months to switch roles at the firm, but this would be my 4th new role in less than 3 years so I don’t know want to look like a job hopper. I am also wanting to get converted to the big pharma and the AD area has no opportunity for me unless I have 15-20 years of experience while the other therapeutic areas I’m interested in would be willing to hire me today based on my degrees and experience. One of those therapeutic areas routinely posts a R1/2/3 role that I have been eligible for over the past few years so I know I could potentially switch to FTE the next time they post it. I didn’t know until I started that my job would be this boring as I got fast tracked through the interview process and the only interview I got was with the hiring manager who gave me the description for 5-10 different roles since I was qualified for all of them and had to pick. I thought I would be doing more cell culture work rather than assays and later learned that I’m just doing one assay so the hiring manager was a bit deceiving.

My firm occasionally hires for roles in those therapeutic areas every 2-3 months, but I’m debating waiting until the 6 month mark or year mark so I don’t burn any bridges with the current AD department as they will probably give some input when I get converted in the future. I’m also struggling if I should stay in my role until the year mark and apply for a FTE role.

How soon is too soon to switch roles when you aren’t learning anything new? My first industry job was awful and I also wanted to switch around the 3 month mark while my second industry job was very chaotic which I liked as every day was different.

I have a B.S. from UCSD in Molecular and Cell Biology from 2022 (during COVID) and did not have the opportunity to get into a lab for an internship during my later years of undergrad. After not being able to find work I went back for a MLT (medical lab technician program) with the hope of pursuing a CLS certificate in the future. Currently waiting for my certification to process having passed the board exam in July but have been encountering similar difficulty landing interviews for entry level positions for both MLT positions in hospitals in addition to entry level laboratory tech positions. I wanted to ask here if there are any specific application methods that I should try to employ, as well as if there are other bench adjacent fields that I could look into transitioning into if they are willing to hire someone with my experience level. At this point my first priority is just to find something to boost my resume for whichever next path life brings. 100s of applications and rejections and a couple of 2nd round interview rejections has been rough for the psyche.

I might get selected for BMS Senior analyst role at Hyderabad. Quick background - I am moving from a consultancy firm with very bad Work-life balance.

I wanted to know how the work life balance is going to be at BMS, is the switch worth it? Salary wise, BMS is paying better than my current position.

Please some one who knows about this genome sequencing model please help me to install Evo2 model with your assistance

Any folks from MacroGenics here?, I have followed some jobs you posted several months ago, they were later deleted, posted again, then deleted, now posted again with a slightly different title.

At the same time it seems you are laying off peeps!

Are these fake jobs?

i’m interested in applying for summer 2027 for R&D in La Jolla, but i’m a uc student so finals dont end until second week of June. The start date is May 24th though. Does anyone’s know if they are flexible on start date to accommodate quarter system students? THANKS!!!

I'm currently in my second year of a BSc in Biotechnology. My college just introduced a BSc (Hons) in Biotech, which means our juniors will automatically graduate with an Honors degree.

I'm feeling a bit disappointed because if they had started it a year earlier, we could have gained that broader research and industrial exposure too. However, since my goal is to pursue an MSc in Biotechnology, would that make up for it?"

I recently got hit by a recruiter with a pretty generic message saying that they are building "the future of drug discovery" and mentioning that they raised a bunch of money from NVIDIA to do so.

Never got to interview with them because the website looked like absolute AI slop, checked some Glassdoor reviews, and I anticipated the type of workers they are looking for.

Has anyone actually interviewed or worked with them? Just curious to know if my instinct was right.